Focus on the scientific assetsGeraldine was able to go public with the results for anti-aging. That is a healthy thing for it not be tied up in some sort of confidentiality protection.
That information was not for our consumption here in my view. I understand that the community in pharma have their ears close to the ground when anything worth paying attention to surfaces.
I don't believe that anything management does or doesn't do should interfere with the value of the asset itself. But it is what it is for now.
I do believe that the current share price is not really in line with the results posted on the clinicals but only the science and business people in that space know for certain - market forces will play out as they should.
Will have to see where this goes when or if players are confirmed at the negotiation table.